One of three successfully treated CGD patients in a Swiss-German gene therapy trial died due to his underlying disease: A position statement from the European Society of Gene Therapy (ESGT).
D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D018450:Disease Progression; D005060:Europe; D017809:Fatal Outcome; D015316:Genetic Therapy / Q000009:adverse effects; D005858:Germany; D006105:Granulomatous Disease, Chronic / Q000150:complications / Q000628:therapy*; D006801:Humans; D007416:Intestinal Perforation / Q000209:etiology; D018805:Sepsis / Q000209:etiology; D012955:Societies, Medical; D013557:Switzerland